225 related articles for article (PubMed ID: 20535606)
1. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.
de Villiers TJ; Chines AA; Palacios S; Lips P; Sawicki AZ; Levine AB; Codreanu C; Kelepouris N; Brown JP
Osteoporos Int; 2011 Feb; 22(2):567-76. PubMed ID: 20535606
[TBL] [Abstract][Full Text] [Related]
2. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.
Christiansen C; Chesnut CH; Adachi JD; Brown JP; Fernandes CE; Kung AW; Palacios S; Levine AB; Chines AA; Constantine GD
BMC Musculoskelet Disord; 2010 Jun; 11():130. PubMed ID: 20569451
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA;
Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271
[TBL] [Abstract][Full Text] [Related]
4. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
[TBL] [Abstract][Full Text] [Related]
5. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
[TBL] [Abstract][Full Text] [Related]
6. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.
Archer DF; Pinkerton JV; Utian WH; Menegoci JC; de Villiers TJ; Yuen CK; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1109-15. PubMed ID: 19543129
[TBL] [Abstract][Full Text] [Related]
7. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.
Palacios S; Silverman SL; de Villiers TJ; Levine AB; Goemaere S; Brown JP; De Cicco Nardone F; Williams R; Hines TL; Mirkin S; Chines AA;
Menopause; 2015 Aug; 22(8):806-13. PubMed ID: 25668306
[TBL] [Abstract][Full Text] [Related]
8. [Bazedoxifene as a new-generation SERM].
Ohta H
Clin Calcium; 2011 Jan; 21(1):34-42. PubMed ID: 21187592
[TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis.
Kawate H; Takayanagi R
Clin Interv Aging; 2011; 6():151-60. PubMed ID: 21753870
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Palacios S
Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
[TBL] [Abstract][Full Text] [Related]
12. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
13. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Hadji P
Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
[TBL] [Abstract][Full Text] [Related]
14. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
Palacios S; Currie H; Mikkola TS; Dragon E
Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
[TBL] [Abstract][Full Text] [Related]
15. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis.
Harvey JA; Holm MK; Ranganath R; Guse PA; Trott EA; Helzner E
Menopause; 2009; 16(6):1193-6. PubMed ID: 19503006
[TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis.
Genant HK
Menopause Int; 2011 Jun; 17(2):44-9. PubMed ID: 21693498
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bazedoxifene in postmenopausal Asian women.
Xu L; Tsai KS; Kim GS; Wu Y; Vincendon P; Chines AA; Constantine GD
Osteoporos Int; 2011 Feb; 22(2):559-65. PubMed ID: 20535607
[TBL] [Abstract][Full Text] [Related]
19. Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424.
Drugs R D; 2008; 9(3):191-6. PubMed ID: 18457472
[TBL] [Abstract][Full Text] [Related]
20. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
